Hinge Health, Inc. (HNGE), a digital musculoskeletal (MSK) care company, is covered by roughly 17 sell-side analysts. Their ratings lean heavily bullish, with a consensus "Buy" and targets ranging from $90 to $140. The arithmetic mean of those targets, however, lands near $112 — only a fraction of a percent above the latest price of $111.52 — so a conventional "average analyst price target" offers no meaningful upside to analyze.
For that reason, this article examines the $130 objective, a figure actively cited in recent Street commentary. BofA raised its target to $130 from $110 while reiterating a Buy rating, and KeyBanc raised its own target to $140 from $125 on an Overweight rating ahead of third-quarter results. These are single-firm views, not a consensus, and the wide $90–$140 spread shows genuine disagreement about how richly the shares should trade. Morgan Stanley ($117), Stifel and Needham ($115 each), Truist ($112), and RBC Capital ($110) cluster in between, while Baird's $90 Neutral rating is the clearest cautious voice.
Hinge Health closed at $111.52 on October 23, 2026, near its 52-week high of $113.48 and up more than 120% over the trailing year. Reaching $130 would require an additional rise of roughly 17%, which is substantial for a stock already trading at an elevated valuation. The company went public in May 2025 at $32, and the shares have since more than tripled as revenue accelerated and the business turned profitable.
The path toward $130 would most plausibly run through continued execution on its AI-powered MSK platform — TrueMotion motion tracking and the FDA-cleared Enso wearable — plus the expansion beyond MSK into areas such as gastrointestinal care following the Cylinder Health acquisition. Continued revenue growth near 50%, sustained gross margins around 86%, and forward guidance raises would be the clearest fundamental fuel. Technically, the stock would first need to clear the $113–$114 all-time-high zone before round-number resistance at $120 and then $130.
Hinge Health's growth remains its strongest argument. Trailing-twelve-month revenue reached about $720 million, with recent quarterly growth near 53% year over year, and the company generated roughly $107 million in trailing net income after years of losses. It serves self-insured employers, health plans, and pharmacy benefit managers, and reported more than 1.5 million lifetime members and a growing client base. Analysts lifting targets in late 2026 have cited strong execution, expanding product scope, and improving unit economics. Momentum in AI-enabled healthcare and a wave of positive analyst revisions provide additional tailwinds.
Valuation is the clearest obstacle. The stock trades at a trailing P/E (price-to-earnings ratio) near 80 and a forward P/E in the low-40s, leaving little room for disappointment. Because the shares sit just below all-time highs, any earnings miss, guidance cut, or slowdown in employer and health-plan demand could trigger valuation compression. Competition in digital musculoskeletal and broader virtual-care markets is intensifying, and integrating the Cylinder Health expansion carries execution risk. KeyBanc itself cautioned that elevated expectations leave the stock vulnerable if top-line growth fails to satisfy investors at current levels.
The $113–$114 zone, the 52-week and all-time high, is the pivotal resistance area; a decisive close above it would open the way toward $120 and then $130. Support sits near $108–$110, the recent breakout region, followed by the psychological $100 level and the 50-day moving average near $95. The 200-day moving average near $65 remains far below, underscoring how far and how quickly the shares have run. Momentum readings have been elevated, consistent with a strongly uptrending but potentially overbought tape.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ. The nearest catalyst is the third-quarter 2026 earnings report scheduled for November 2, 2026. Investors should watch revenue growth, gross margin, client and member additions, guidance for the remainder of the year, and any commentary on the gastrointestinal-care expansion. Subsequent analyst revisions — up or down — will be the most direct signal of whether the $130 objective remains in view.
For traders tracking names like Hinge Health, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Consider using it alongside your own research to stay ahead of evolving market signals.
Hinge Health reaching $130 would require a substantial move of roughly 17% from the latest close, and the objective rests on recent single-firm targets rather than a broad consensus. Strong revenue growth, expanding margins, a newly profitable business, and positive analyst revisions support the case, while a rich valuation, an all-time-high share price, and execution risk on newer product lines argue for caution. The $90–$140 analyst range reflects real disagreement about how much the growth story is worth. With earnings due in early November, guidance and revisions — not momentum alone — will determine whether $130 remains a realistic destination.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HNGE has been loosely correlated with OMDA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if HNGE jumps, then OMDA could also see price increases.
| Ticker / NAME | Correlation To HNGE | 1D Price Change % | ||
|---|---|---|---|---|
| HNGE | 100% | +0.85% | ||
| OMDA - HNGE | 54% Loosely correlated | -0.20% | ||
| TEM - HNGE | 35% Loosely correlated | -4.62% | ||
| TDOC - HNGE | 34% Loosely correlated | -0.45% | ||
| DOCS - HNGE | 32% Poorly correlated | -1.37% | ||
| VEEV - HNGE | 31% Poorly correlated | -0.28% | ||
More | ||||
| Ticker / NAME | Correlation To HNGE | 1D Price Change % |
|---|---|---|
| HNGE | 100% | +0.85% |
| Services to the Health Industry industry (42 stocks) | 15% Poorly correlated | -0.05% |
| Health Services industry (239 stocks) | 2% Poorly correlated | -1.13% |